Skip to content
Review

Artificial Intelligence for Natural Products Discovery and Development.

Sep 2026 · Current Topics in Medicinal Chemistry · 0 citations
Medicine

TL;DR

This review comprehensively surveys recent advances in AI applications across the full NP discovery and development pipeline, encompassing genome mining, structure-based and ligand-based virtual screening, multimodal structural characterization, lead optimization, and biosynthetic pathway engineering.

Abstract

Natural products (NPs) remain a cornerstone of modern drug discovery, offering stereochemical complexity and diverse bioactivities that precisely modulate therapeutic targets, refined through billions of years of evolution. However, their research has long been hindered by inefficient, empirical workflows, high resource consumption, structural complexity, and the "multicomponent, multi-target" nature of their mechanisms. The exponential growth of genomic, metabolomic, and spectral data has overwhelmed conventional analytical methods, exposing critical bottlenecks in handling high-dimensional, heterogeneous datasets that exceed human interpretive capacity. Artificial intelligence (AI) is emerging as a transformative paradigm to address these challenges, integrating multi-omics and chemical data to shift NP research from fragmented empiricism toward mechanism-driven, precision-oriented development. By leveraging deep learning architectures- including graph neural networks, Transformers, and diffusion-based generative models-AI enables systematic decoding of NP biosynthesis, automated structure elucidation, rational target identification, knowledge extraction from vast unstructured scientific literature, and de novo molecular design. This review comprehensively surveys recent advances in AI applications across the full NP discovery and development pipeline, encompassing genome mining, structure-based and ligand-based virtual screening, multimodal structural characterization, lead optimization, and biosynthetic pathway engineering. We further examine the emerging roles of protein-centric, molecule- centric, and multimodal foundation models, as well as large language models, in bridging genotype-to-chemotype gaps and unlocking unstructured scientific knowledge. Finally, we discuss critical challenges including data scarcity, representational limitations for complex stereochemistry, physical plausibility in generative models, and the urgent need for experimental validation, while outlining future directions toward autonomous experimentation, closed-loop optimization, and human-AI collaborative discovery.

View source

Similar papers

#graph neural networks Review Open access Sep 2026

Bridging Nature, Data, and Artificial Intelligence: An Interdisciplinary Approach for Natural Products Discovery

Natural products (NPs) continue to serve as a foundational source for drug leads, owing to their unique chemical architectures, evolutionary optimisation, and structural diversity. Nevertheless, conventional natural product discovery is slow, resource-intensive, and constrained by rediscovery, dereplication inefficienc...

N. Hegazi · 0 citations
Review Open access Sep 2026

APPLICATIONS OF DATA ANALYSIS AND ARTIFICIAL INTELLIGENCE AGENTS IN NOVEL DRUG DISCOVERY: A CRITICAL LITERATURE REVIEW

This evidence-based literature review critically examines the evolution and application of computational technologies across the pharmaceutical pipeline, ranging from early expert systems like DENDRAL, computer-aided drug design (CADD), and quantitative structure-activity relationship (QSAR) modeling to AlphaFold 3 bio...

Leonardo Mairene Muniz · 0 citations
Review Sep 2026

Artificial Intelligence in the Discovery of Bioactive Natural Products.

Artificial intelligence (AI) is transforming natural products discovery by integrating genome mining, metabolomics, bioactivity prediction, and virtual screening into unified computational ecosystems. This review provides a comprehensive overview of AIdriven approaches for the discovery of bioactive natural products, c...

A. Rahman, Asia · 0 citations
#diffusion models Review Open access Sep 2026

Artificial intelligence-driven drug discovery: a deep learning paradigm shift in pharmaceutical research and development

To bridge the gap between in silico predictions, chemical synthesis, and biological reality, emerging solutions such as federated learning, causality-aware Explainable AI, closed-loop autonomous laboratories, and efficiency-oriented algorithmic strategies are explored.

Xue-Yuan Bi, Yang-Yang Wang, Ji-Han Wang et al. · 0 citations
Review Sep 2026

Artificial Intelligence-Based Halogenated Chalcone Drug Discovery: An Integrated Framework for Rational Anticancer Lead Optimization

Halogenated chalcones are emerging as an exciting class of potential anticancer scaffolds with respect to medicinal chemistry; they exhibit structural flexibility, multitarget pharmacology, and allow for rapid medicinal chemistry optimization. The biological activity associated with halogen substitutions on the scaffol...

Tamara Bassam Kamal Hijjawi · 0 citations
Review Sep 2026

Precision Drug Discovery in the Era of Artificial Intelligence: A Critical Review.

A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.

Meng Liu, Jia-Cheng Xiong, Ming-Yue Zheng · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.